Pulse afatinib for ERBB2 exon 20 insertion mutated lung adenocarcinomas

INTRODUCTION: Genomic aberrations involving erb-b2 receptor tyrosine kinase 2 (ERBB2) are driver oncogenes in ∼2% of lung adenocarcinomas. However, the use of daily dosing of ERBB2 tyrosine kinase inhibitors (TKIs) - including afatinib - has been fraught by plasma concentrations that barely achieve...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Thorac Oncol
Egile Nagusiak: Costa, Daniel B., Jorge, Susan E., Moran, Jason P., Freed, Jason A., Zerillo, Jessica A., Huberman, Mark S., Kobayashi, Susumu S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4877224/
https://ncbi.nlm.nih.gov/pubmed/26964772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2016.02.016
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak